<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03314987</url>
  </required_header>
  <id_info>
    <org_study_id>17.1067</org_study_id>
    <nct_id>NCT03314987</nct_id>
  </id_info>
  <brief_title>Nucleophilic Defense Against PM Toxicity (NEAT Trial)</brief_title>
  <acronym>NEAT</acronym>
  <official_title>Nucleophilic Defense Against PM Toxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carnosine is a naturally occurring peptide found in high levels in skeletal muscle and the
      brain and is also available commercially as a dietary supplement. Since carnosine has
      anti-oxidant properties and air pollution exposure induces a state of oxidative stress, the
      purpose of this study is to see if those taking carnosine as a dietary supplement are
      protected from air pollution-induced oxidative stress and adverse cardiovascular outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a placebo controlled, randomized, double-blind, interventional trial investigating
      the efficacy of carnosine in reducing the effects of particulate matter air pollution
      (PM2.5). A total of 240 participants from the Louisville metropolitan and neighboring areas
      will be randomized into two dietary supplement study groups - carnosine (n=120) versus
      placebo (n=120). Intervention of study dietary supplements will occur from May through
      September, when the levels of PM2.5.are highest in the Louisville, KY area. Study
      participants will be given a daily oral dose of total of 2 grams of carnosine (or placebo)
      for a total of 12 consecutive weeks (during May through September).

      Urinary levels of carnosine will be used to screen and identify potential candidates with low
      carnosine levels. Those with levels less than the median levels of the population, will be
      invited to participate in the study. The following measurements will be performed - blood and
      urine sample collection, physical examination, arterial stiffness, physical function, and
      self-reported surveys on environmental exposure, sleep, diet, and exercise. Supplement
      intervention (carnosine or placebo) will be initiated at the time of Baseline Assessment and
      will continue for 12 weeks from that date. Two follow up visits will occur at 6 weeks and 12
      weeks respectively after initiating supplementation.

      This innovative clinical investigation will provide an insight into the pre and post
      intervention effects of a cheap, safe, and over-the-counter available dietary supplement in
      countering the effects of air pollution.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>placebo controlled, randomized, double-blind</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double blind (participant, investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>endothelial progenitor cells</measure>
    <time_frame>3 months</time_frame>
    <description>circulating pro-angiogenic cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>arterial stiffness</measure>
    <time_frame>3 months</time_frame>
    <description>index of arterial function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endothelial microparticles</measure>
    <time_frame>3 months</time_frame>
    <description>index of endothelial damage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelet monocyte aggregates</measure>
    <time_frame>3 months</time_frame>
    <description>index of platelet activation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Air Pollution Toxicity</condition>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each participant will be given a daily oral dose of 2 grams of carnosine for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each participant will be given a daily oral dose of 2 grams of placebo for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-carnosine</intervention_name>
    <description>a naturally occurring di-peptide</description>
    <arm_group_label>intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>an identically appearing supplement</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Individuals between 22-65 years of age of either gender and all ethnicities,

          2. All genders and all ethnicities

          3. Residing in or near the Louisville metropolitan area

          4. Consumes some type of meat/fish at least once a month during the past 3 months

          5. Carnosine levels below the median level of the population

          6. Agrees to complete all study visits and follow study intervention regimen

          7. Will be living in the study area throughout the study period, with no more than 1 week
             away from the study area.

        Exclusion Criteria:

          1. Consumed any dietary supplement more than 3 times per week in the past 4 weeks (one
             month)

          2. Current / ongoing treatment for substance abuse

          3. Currently undergoing treatment or have conditions which may cause participant to be
             immunosuppressed

          4. Diseases Affecting Peripheral Cell Count (i.e. Autoimmune Diseases - Hashimoto,
             Rheumatoid Arthritis, SLE, Rheumatoid Arthritis, Sjogren syndrome, Ankylosing
             Spondylitis, Takayasu arteritis, Kawasaki disease, Polyarteritis nodosa.)

          5. Diseases Affecting Bone Marrow capacity

          6. Diagnosis of any active cancer

          7. Recent organ / kidney transplant or replacement (Active/Long-Term Medications)

          8. Type 1 Diabetes Mellitus

          9. Untreated thyroid disease

         10. Untreated anemia

         11. Current acute infections (Influenza, fever, etc.)

         12. HIV positive status

         13. Active/current Hepatitis HepA, HepB or HepC or in past 6 months

         14. Currently or planning to be Pregnant / lactating

         15. Prisoners / vulnerable populations

         16. Other medical conditions that compromise completion of study

         17. Unwilling to provide consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Timothy E O'Toole, Ph.D.</last_name>
    <phone>502-852-5886</phone>
    <email>teotoo01@louisville.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alok Amraotkar, M.D.</last_name>
    <phone>502-852-7559</phone>
    <email>alok.amraotkar@louisville.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>O'Toole TE, Hellmann J, Wheat L, Haberzettl P, Lee J, Conklin DJ, Bhatnagar A, Pope CA 3rd. Episodic exposure to fine particulate air pollution decreases circulating levels of endothelial progenitor cells. Circ Res. 2010 Jul 23;107(2):200-3. doi: 10.1161/CIRCRESAHA.110.222679. Epub 2010 Jul 1.</citation>
    <PMID>20595651</PMID>
  </reference>
  <results_reference>
    <citation>Barski OA, Xie Z, Baba SP, Sithu SD, Agarwal A, Cai J, Bhatnagar A, Srivastava S. Dietary carnosine prevents early atherosclerotic lesion formation in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2013 Jun;33(6):1162-70. doi: 10.1161/ATVBAHA.112.300572. Epub 2013 Apr 4.</citation>
    <PMID>23559625</PMID>
  </results_reference>
  <results_reference>
    <citation>Pope CA 3rd, Bhatnagar A, McCracken JP, Abplanalp W, Conklin DJ, O'Toole T. Exposure to Fine Particulate Air Pollution Is Associated With Endothelial Injury and Systemic Inflammation. Circ Res. 2016 Nov 11;119(11):1204-1214. doi: 10.1161/CIRCRESAHA.116.309279. Epub 2016 Oct 25.</citation>
    <PMID>27780829</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 16, 2017</study_first_submitted>
  <study_first_submitted_qc>October 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2017</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Timothy Edward O'Toole</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>air pollution</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>intervention</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

